ligands acting on targets

(R)-Omeprazole Sodium Salt, the R-Form of Omeprazole. Acts as a gastric proton-pump inhibitor. (R)-Omeprazole Sodium Salt is an inhibitor of ATP4, CYP2C19, CYP2C9 and CYP3A.

(R)-Omeprazole Sodium Salt, the R-Form of Omeprazole. Acts as a gastric proton-pump inhibitor. (R)-Omeprazole Sodium Salt is an inhibitor of ATP4, CYP2C19, CYP2C9 and CYP3A.

Information(R)-P7C3-Ome is an analogue of P7C3 and P3C3-A20. (R)-P7C3-Ome has therapeutic benefits in neuropsychiatric and/or neurodegenerative disease and is far more active than the S-enantiomer.

(R)-PFI 2 hydrochloride.

(R)-PFI 2 hydrochloride.

(R)-PFI 2 hydrochloride.

(R)-PFI 2 hydrochloride.

(R)-PFI 2 hydrochloride.

(R)-PFI 2 hydrochloride.

(R)-Phenoxybenzamine Hydrochloride is an irreversible α-adrenergic antagonist. Used in the treatment of hypertension, it has a relatively slow onset and prolonged effect when compared to alternative α-adrenergic blockers.

(R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib. Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor , inhibits diverse BTK C481 substitution mutations.Form:Solid.

(R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib. Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor , inhibits diverse BTK C481 substitution mutations.Form:Solid.